BioNTech
BNTX
281 hedge funds and large institutions have $4.36B invested in BioNTech in 2026 Q2 according to their latest regulatory filings, with 43 funds opening new positions, 93 increasing their positions, 71 reducing their positions, and 30 closing their positions.
43% more first-time investments, than exits
New positions opened: 43 | Existing positions closed: 30
31% more repeat investments, than reductions
Existing positions increased: 93 | Existing positions reduced: 71
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
3% more funds holding
Funds holding: 272 → 281 (+9)
3% more capital invested
Capital invested by funds: $4.22B → $4.36B (+$141M)
0.35% less ownership
Funds ownership: 18.91% → 18.55% (-0.35%)
30% less call options, than puts
Call options by funds: $117M | Put options by funds: $166M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$175M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
+$95.5M |
| 3 |
Goldman Sachs
New York
|
+$46.4M |
| 4 |
DCP
Davern Capital Partners
Ny,
New York
|
+$42.3M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$39.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$357M |
| 2 |
Flossbach Von Storch
Cologne,
Germany
|
-$137M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$55.2M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$39.2M |
| 5 |
BNP Paribas Financial Markets
Paris,
France
|
-$31.3M |
BNTX Hedge Fund Activity: Q2 2026 in Review
281 of the 8,279 institutional investors tracked by Wall St. Rank reported a position in BioNTech (BNTX) for Q2 2026, worth a combined $4.36B — up 3.4% from $4.22B a quarter earlier.
Buyers outnumbered sellers: 43 funds opened new BNTX positions and 30 closed out — a net gain of 13 holders — while 93 added to existing stakes and 71 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $175M. The largest seller was T. Rowe Price Investment Management, cutting an estimated $357M.
- 281 institutional investors held BioNTech (BNTX) as of Q2 2026, up from 272 in Q1 2026.
- Funds reported $4.36B of BioNTech stock for Q2 2026, up 3.4% quarter-over-quarter.
- 43 funds opened new BioNTech positions in Q2 2026 and 30 closed out, a net change of +13 holders.
- The largest BioNTech buyer in Q2 2026 was Fidelity Investments, an estimated $175M added.
- The largest BioNTech seller in Q2 2026 was T. Rowe Price Investment Management, an estimated $357M sold.
Based on aggregated 13F filings for Q2 2026.